Floatz logo

Entacapone

Pure Autonomic Failure

Daniel ClaassenSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Pure Autonomic Failure cohort.

Asset / SponsorPhaseRating
Droxidopa
Vanderbilt University Medical Center
Phase 3BB
Midodrine
Vanderbilt University Medical Center
Phase 1CCC
Ampreloxetine
Theravance Biopharma
Phase 3CCC
(1S,2S)-(+)-PSEUDOEPHEDRINE
Vanderbilt University
Phase 1CC
Trimetaphan
Vanderbilt University
Phase 1CC

View all 9 →

Same molecule, other indications

Entacapone is also rated in:

Parkinson diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
autonomic nervous system disorderActive
CCC
Indicative · Phase 1/2
54 / 100
View asset →
multiple system atrophyActive
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →